Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported an open-market sale of 3,342 shares of common stock at a weighted average price of $5.0649 per share on May 18, 2026. The footnotes state this sale was made to cover tax obligations arising from the release of restricted stock units, indicating it was a tax-related transaction rather than a discretionary portfolio move. Following the sale, he directly holds 336,764 shares of Lexeo common stock, which includes 252,130 restricted stock units.

Insights

Equity compensation and insider trading analyst

CEO’s small Lexeo share sale is tax-driven and routine.

The CEO of Lexeo Therapeutics, Richard Nolan Townsend, sold 3,342 shares of common stock at a weighted average price of $5.0649 per share. The filing specifies this was to cover tax obligations from the release of restricted stock units, a common administrative event tied to equity compensation.

After the transaction, he still holds 336,764 shares, including 252,130 restricted stock units, so the sale represents a small portion of his overall stake. Because the purpose is tax withholding rather than a discretionary reduction in exposure, the informational value of this sale for assessing sentiment toward the stock is limited.

Insider Trade Summary

Net Seller: 3,342 shares ($16,927)

Net Sell 1 txn

Insider Townsend Richard Nolan

Role Chief Executive Officer

Sold 3,342 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,342	$5.0649	$17K

Holdings After Transaction: Common Stock — 336,764 shares (Direct, null)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $5.03 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 252,130 Restricted Stock Units.

Key Figures

Shares sold: 3,342 shares Sale price: $5.0649 per share Shares held after: 336,764 shares +2 more

5 metrics

Shares sold 3,342 shares Open-market sale on May 18, 2026

Sale price $5.0649 per share Weighted average sale price for the transaction

Shares held after 336,764 shares Direct holdings following the sale

RSUs included 252,130 RSUs Restricted Stock Units included in post-transaction holdings

Price range $5.03–$5.11 Range of individual trade prices in the sale

Key Terms

Restricted Stock Units, open-market sale, weighted average sale price, tax obligations

4 terms

Restricted Stock Units financial

"Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

tax obligations financial

"Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs")."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		S(1)		3,342	D	$5.0649(2)	336,764(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $5.03 to $5.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 252,130 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lexeo Therapeutics (LXEO) CEO report in the latest Form 4?

Lexeo Therapeutics CEO Richard Nolan Townsend reported selling 3,342 common shares at a weighted average price of $5.0649 on May 18, 2026. The filing explains this was done specifically to cover tax obligations arising from the release of restricted stock units, not a discretionary sale.

How many Lexeo Therapeutics (LXEO) shares did the CEO sell and at what price?

The CEO sold 3,342 shares of Lexeo Therapeutics common stock at a weighted average price of $5.0649 per share. The transaction was executed in multiple trades between $5.03 and $5.11, with the reported figure representing the calculated weighted average sale price.

Why did the Lexeo Therapeutics (LXEO) CEO sell shares in this Form 4 filing?

The CEO’s sale was to cover tax obligations from the release of restricted stock units. The footnote clearly states the transaction represents a sale to satisfy tax liabilities tied to equity compensation, which is a routine occurrence when RSUs vest and become taxable.

How many Lexeo Therapeutics (LXEO) shares does the CEO hold after this transaction?

Following the sale, the CEO directly holds 336,764 shares of Lexeo Therapeutics common stock. This total includes 252,130 restricted stock units, showing that despite the tax-related sale, he maintains a substantial ongoing equity position in the company.

Are restricted stock units included in the Lexeo Therapeutics (LXEO) CEO’s reported holdings?

Yes. The filing notes that the CEO’s 336,764-share position includes 252,130 restricted stock units. RSUs are stock-based awards that typically vest over time, and once vested, they can trigger tax liabilities, which in this case led to the reported sale.

Was the Lexeo Therapeutics (LXEO) CEO’s Form 4 sale a typical open-market sale?

While coded as an open-market sale, the filing clarifies it was conducted to cover tax obligations on RSU release. That makes it more of an administrative, compensation-related transaction rather than a discretionary decision to reduce exposure to Lexeo Therapeutics shares.